Rankings
▼
Calendar
IOVA
Iovance Biotherapeutics, Inc.
$2B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
Gross Profit
-$10M
-804.5% margin
Operating Income
-$461M
-38735.0% margin
Net Income
-$444M
-37345.4% margin
EPS (Diluted)
$-1.89
Cash Flow
Operating Cash Flow
-$362M
Free Cash Flow
-$384M
Stock-Based Comp.
$63M
Balance Sheet
Total Assets
$780M
Total Liabilities
$196M
Stockholders' Equity
$585M
Cash & Equivalents
$115M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1M
$0
—
Gross Profit
-$10M
$0
—
Operating Income
-$461M
-$399M
-15.5%
Net Income
-$444M
-$396M
-12.2%
← Q4 2022
All Quarters
Q1 2023 →
IOVA FY 2023 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena